The estimated Net Worth of Venture Partners Ii, Lp Sca... is at least 109 百万$ dollars as of 29 November 2010. Venture Sca owns over 1,839,645 units of Zogenix Inc stock worth over 108,628,847$ and over the last 14 years Venture sold ZGNX stock worth over 0$.
Venture has made over 1 trades of the Zogenix Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Venture bought 1,839,645 units of ZGNX stock worth 7,358,580$ on 29 November 2010.
The largest trade Venture's ever made was buying 1,839,645 units of Zogenix Inc stock on 29 November 2010 worth over 7,358,580$. On average, Venture trades about 1,839,645 units every 0 days since 2010. As of 29 November 2010 Venture still owns at least 4,071,546 units of Zogenix Inc stock.
You can see the complete history of Venture Sca stock trades at the bottom of the page.
Over the last 14 years, insiders at Zogenix Inc have traded over 5,100,850$ worth of Zogenix Inc stock and bought 57,764,538 units worth 193,451,745$ . The most active insiders traders include Advisors Llcperceptive Life...、Nicole Vitullo、Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of 13,059,406$. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth 15,000$.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: